DEVELOPMENT
The pdf-version - Eesti Koostöö Kogu
The pdf-version - Eesti Koostöö Kogu
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Figure 1.4.3<br />
Usage of tranquilisers and anti-depressants 1999-2008<br />
Tranquilisers and sleep aids<br />
Anti-depressants<br />
90<br />
Estonia Finland Sweden<br />
80<br />
70<br />
60<br />
50<br />
40<br />
1999<br />
2000<br />
2001<br />
2002<br />
2003<br />
2004<br />
2005<br />
2006<br />
2007<br />
2008<br />
1999<br />
2000<br />
2001<br />
2002<br />
2003<br />
2004<br />
2005<br />
2006<br />
2007<br />
2008<br />
1999<br />
2000<br />
2001<br />
2002<br />
2003<br />
2004<br />
2005<br />
2006<br />
2007<br />
2008<br />
In daily doses per 1,000 residents per year<br />
30<br />
20<br />
10<br />
0<br />
sand use medications in normal dosages every day. The<br />
Table and the initial data in Figure 1.3.3 originate from<br />
the medication statistics of the Estonian State Agency<br />
of Medicines (http://www.ravimiamet.ee/) and the<br />
database of the Nordic Medico-Statistical Committee<br />
(http://www.nom-nos.dk).<br />
For instance, in Estonia in 2000, the total medication<br />
usage for gastric and duodenal ulcers was 10<br />
DPD/1000/per 24 hours, i.e. 10 people in a thousand<br />
(1% of the population) could be using these medications<br />
in normal doses every day throughout the year. This is<br />
a statistical average, because in real life, some people<br />
take larger doses, some do not use any medications at<br />
all, while others may be using several at the same time.<br />
Unfortunately, it is not possible to compare the data on<br />
the use of medications in Estonia with any other states in<br />
the world, besides the Nordic countries, because only in<br />
these states do representative sales statistics for medications<br />
exist that cover the entire population and provide a<br />
reliable indirect assessment of the amounts of medications<br />
used by the population.<br />
During the last 10 years, the total usage of prescription<br />
drugs in Estonia has increased by half and,<br />
by 2010, arrived at approximately the same level as<br />
in the Nordic countries ten years ago. However, the<br />
amount used in Estonia continues to be half of that<br />
in the Nordic countries, because the increase in absolute<br />
quantities (459 DPD/1000/per day) has been even<br />
greater than in Estonia (311 DPD/1000/per day). In<br />
2000, a total of 1074 DPD/1000/per day were consumed,<br />
i.e. everyone (from newborns to the elderly)<br />
could be taking one ordinary dose of a prescription<br />
medication per day. In 2010, the average amount was<br />
already 1.5 ordinary doses of prescription medications<br />
per resident per day.<br />
What can we conclude from this – are there more<br />
illnesses, or are they being treated more vigorously?<br />
Maybe the longer life spans and additional years of disability-free<br />
life in the Nordic countries and Estonia are the<br />
result of the increase in medication usage? The medication<br />
manufacturers and sellers would like this explanation, but<br />
it is unlikely to be true.<br />
Anxiety and worry, sleeplessness and depression<br />
are an increasingly significant part of modern life,<br />
while we also know how to and want to influence<br />
these conditions with medication. Figure 1.4.3 shows<br />
the dynamics of the use of tranquilisers, sleep aids<br />
and anti-depressants for the treatment of anxiety and<br />
mood disturbances in Estonia, Finland and Sweden.<br />
For instance, in 2008, the amount of tranquilisers and<br />
sleep aids used in Finland totalled 84 DPD/1000/per<br />
day, i.e. 8.4% of the Finnish population could be taking<br />
one dose of tranquilisers every day throughout the<br />
year. But hopefully, they are not using them on a daily<br />
basis, because, as a rule, these medications lose their<br />
effect if used regularly. The impact of anti-depressants<br />
manifests itself after longer usage, and the quantities<br />
of these medications taken in Finland and Sweden<br />
44<br />
Estonian Human Development Report 2012/2013